574 related articles for article (PubMed ID: 20538126)
21. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
[TBL] [Abstract][Full Text] [Related]
24. A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe.
Stef MA; Palacios L; Olano-Martín E; Foe-A-Man C; van de Kerkhof L; Klaaijsen LN; Molano A; Schuurman EJ; Tejedor D; Defesche JC
J Mol Diagn; 2013 May; 15(3):362-72. PubMed ID: 23537714
[TBL] [Abstract][Full Text] [Related]
25. Molecular spectrum of autosomal dominant hypercholesterolemia in France.
Marduel M; Carrié A; Sassolas A; Devillers M; Carreau V; Di Filippo M; Erlich D; Abifadel M; Marques-Pinheiro A; Munnich A; Junien C; ; Boileau C; Varret M; Rabès JP
Hum Mutat; 2010 Nov; 31(11):E1811-24. PubMed ID: 20809525
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
27. An APEX-based genotyping microarray for the screening of 168 mutations associated with familial hypercholesterolemia.
Dušková L; Kopečková L; Jansová E; Tichý L; Freiberger T; Zapletalová P; Soška V; Ravčuková B; Fajkusová L
Atherosclerosis; 2011 May; 216(1):139-45. PubMed ID: 21310417
[TBL] [Abstract][Full Text] [Related]
28. Limited mutational heterogeneity in the LDLR gene in familial hypercholesterolemia in Tunisia.
Jelassi A; Jguirim I; Najah M; Abid AM; Boughamoura L; Maatouk F; Rouis M; Boileau C; Rabès JP; Slimane MN; Varret M
Atherosclerosis; 2009 Apr; 203(2):449-53. PubMed ID: 18757057
[TBL] [Abstract][Full Text] [Related]
29. [Familial hypercholesterolemia in Tunisia].
Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
[TBL] [Abstract][Full Text] [Related]
30. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic.
Tosi I; Toledo-Leiva P; Neuwirth C; Naoumova RP; Soutar AK
Atherosclerosis; 2007 Sep; 194(1):102-11. PubMed ID: 17094996
[TBL] [Abstract][Full Text] [Related]
31. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
32. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
33. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
34. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.
Alves AC; Etxebarria A; Soutar AK; Martin C; Bourbon M
Hum Mol Genet; 2014 Apr; 23(7):1817-28. PubMed ID: 24234650
[TBL] [Abstract][Full Text] [Related]
35. Targeted Genetic Analysis in a Chinese Cohort of 208 Patients Related to Familial Hypercholesterolemia.
Wang H; Yang H; Liu Z; Cui K; Zhang Y; Zhang Y; Zhao K; Yin K; Li W; Zhou Z
J Atheroscler Thromb; 2020 Dec; 27(12):1288-1298. PubMed ID: 32759540
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
[TBL] [Abstract][Full Text] [Related]
37. LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.
Snozek CL; Lagerstedt SA; Khoo TK; Rubenfire M; Isley WL; Train LJ; Baudhuin LM
Eur J Hum Genet; 2009 Jan; 17(1):85-90. PubMed ID: 18648394
[TBL] [Abstract][Full Text] [Related]
38. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
Shin DG; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee JH; Lee SH
Atherosclerosis; 2015 Nov; 243(1):53-8. PubMed ID: 26343872
[TBL] [Abstract][Full Text] [Related]
39. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
[TBL] [Abstract][Full Text] [Related]
40. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.
Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J
BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
